(car- fil-zoe- mib) ,


(trade name)


Therapeutic: antineoplastics
Pharmacologic: proteasome inhibitors
Pregnancy Category: D


Treatment of multiple myeloma in patients whose disease has progressed despite previous therapy with bortezomib and immunotherapy in the previous 60 days.


Acts as a proteasome inhibitor by binding to sites on the 20s proteasome. Has antiproliferative and proapoptotic activity.

Therapeutic effects

Delayed progression of multiple myeloma.


Absorption: IV administration results in complete bioavailability.
Distribution: Unknown.
Metabolism and Excretion: Rapidly and extensively metabolized by extrahepatic enzymes. Metabolites have no antineoplastic activity.
Half-life: Unknown.

Time/action profile (proteasome inhibition)

IVwithin 1 hrunknown>48 hr


Contraindicated in: Obstetric: Pregnancy (may cause fetal harm); Lactation: Breast feeding should be avoided.
Use Cautiously in: History of cardiovascular disease (may ↑ risk of adverse cardiovascular reactions, safe and effective use in patients with New York Heart Association Class III and IV heart failure has not been established); Large tumor load (↑ risk of tumor lysis syndrome); Dehydration, diarrhea or electrolyte abnormalities (correct prior to treatment); Hepatic impairment (safe and effective use has not been established); End stage renal disease (dose should be administered following dialysis); Pediatric: Safe and effective use in children has not been established.

Adverse Reactions/Side Effects

Central nervous system

  • dizziness (most frequent)
  • fatigue (most frequent)
  • headache (most frequent)
  • insomnia (most frequent)
  • weakness (most frequent)


  • cough (most frequent)
  • dyspnea (most frequent)


  • heart failure (life-threatening)
  • hypertension (most frequent)
  • myocardial ischemia (life-threatening)
  • peripheral edema (most frequent)
  • pulmonary hypertension


  • hepatic failure (life-threatening)
  • anorexia (most frequent)
  • constipation (most frequent)
  • diarrhea (most frequent)
  • hepatic toxicity
  • nausea


  • renal failure


  • hypoglycemia (most frequent)

Fluid and Electrolyte

  • hypercalcemia (most frequent)
  • hypokalemia (most frequent)
  • hyponatremia (most frequent)
  • hypomagnesemia (most frequent)
  • hypophosphatemia (most frequent)


  • thrombocytopenia
  • anemia (most frequent)
  • leukopenia (most frequent)
  • lymphopenia


  • back pain (most frequent)
  • chest wall pain (most frequent)
  • muscle spasms (most frequent)


  • hypoesthesia (most frequent)
  • peripheral neuropathy


  • tumor lysis syndrome (life-threatening)
  • fever/chills (most frequent)
  • infusion reactions


Drug-Drug interaction

None noted.


Intravenous (Adults) Cycle 1—20 mg/m2 daily for 2 days weekly for 3 wk (days 1, 2, 8, 9, 15 and 16) followed by 12 day rest (days 17–28). Cycle 2 and subsequent cycles—If cycle 1 is tolerated dose should be increased to 27 mg/m2 and continued until unacceptable toxicity or disease progression. Dosa adjustments are required for hematologic, cardiac, pulmonary, renal, neurologic and hepatic toxicity.


Lyophilized powder for IV injection (requires reconstitution): 60 mg/vial

Nursing implications

Nursing assessment

  • Maintain hydration status throughout therapy. Monitor for dehydration and fluid overload.
  • Monitor for cardiac complications (new or worsening CHF, decreased left ventricular function, myocardial ischemia). Withhold dose for Grade 3 or 4 cardiac events until recovery. Consider restarting at a reduced dose. If tolerated, dose may be escalated to previous dose.
  • Assess for pulmonary hypertension with cardiac imaging. Withhold dose until resolved or returned to baseline. Consider restarting based on risk/benefit ratio. May use a reduced dose and escalate as tolerated.
  • Monitor for dyspnea frequently during therapy. Interrupt therapy until symptoms resolved; consider restarting with one dose level reduction and increase as tolerated.
  • Assess for sensory and motor peripheral neuropathy periodically during therapy. If Grade 3 or 4 occurs, withhold dose until resolved or returned to baseline. Restart with prior or reduced dose, may escalate if tolerated.
  • Lab Test Considerations: Monitor CBC and platelet count frequently during therapy. Nadir of thrombocytopenia occurs around Day 8 of 28–day cycle and recovery to baseline by start of next 28–day cycle. Withhold dose for Grade 4 thrombocytopenia or Grade 3 neutropenia. If recovered to baseline, continue with same dose. If recovered to Grade 3 thrombocytopenia or Grade 2 neutropenia, reduce dose by one dose level; may escalate if tolerated.
    • Monitor liver enzymes frequently during therapy. May cause ↑ serum transaminases and bilirubin. If Grade 3 or 4 ↑ of transaminases, bilirubin, or other liver abnormalities withhold dose until resolved or return to baseline. May be restarted at a reduced dose with frequently liver function monitoring; may escalate dose if tolerated.
    • Monitor renal function frequently during therapy. If serum creatinine ≥2 times baseline, withhold dose until recovered to Grade 1 or to baseline. If renal function decline in attributed to therapy restart at a reduced dose; if not restart at prior dose. May escalate dose if tolerated.
    • May cause hyperglycemia, hypercalcemia, hypophosphatemia, and hyponatremia.

Potential Nursing Diagnoses

Activity intolerance


  • Hydrate patient to reduce risk of renal toxicity and tumor lysis syndrome. Prior to each dose administer 250–500 mL IV of 0.9% NaCl or other appropriate fluid. Administer another 250–500 mL as needed following therapy.
    • Premedicate with dexamethasone 4 mg PO or IV prior to all doses of Cycle 1 and prior to all doses during first cycle of dose escalation. Reinstate if symptoms develop during subsequent cycles.
  • Intravenous Administration
  • Intermittent Infusion: Reconstitute each vial by injecting 29 mL Sterile Water for injection directed onto inside wall of vial to minimize foaming. Swirl gently or invert slowly for 1 min or until complete dissolution of powder; do not shale. If foaming occurs, allow solution to rest for 2–5 min until foaming subsides. Solution should be clear and colorless; do not administer solutions that are discolored or contain particulate matter. Diluent: Withdraw calculated dose from vial and dilute in 50 mL D5W. Vial may exceed required dose; calculate dose carefully to prevent overdosing. Reconstituted solution is stable at room temperature for 4 hrs and 24 hrs if refrigerated. Discard unused portion.
  • Rate: Infuse over 2–10 min; do not administer as a bolus. Flush line with 0.9% NaCl or D5W prior to and following administration.
  • Y-Site Incompatibility: Do not mix with or infuse with other medications.

Patient/Family Teaching

  • Explain purpose of medication to patient.
  • Advise patient to notify health care professional if infusion reactions (fever, chills, rigors, arthralgia, myalgia, facial flushing, facial edema, vomiting, weakness, shortness of breath, hypotension, syncope, chest tightness, chest pain, cough, swelling of feet or legs) occur. May occur immediately or up to 24 hrs after administration.
  • May cause fatigue, dizziness, fainting, and drop in BP. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
  • Advise patient to maintain hydration status during therapy.
  • Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
  • Advise female patients to use effective contraception during therapy and to avoid breastfeeding.

Evaluation/Desired Outcomes

  • Slowed progression of multiple myeloma.
References in periodicals archive ?
Combined with Carfilzomib for Treatment of Relapsed Multiple Myeloma Patients," discloses updated findings from a pilot study (NCI-9603) in patients with relapsed or refractory multiple myeloma treated using the combination of carfilzomib and REOLYSIN[sup.
Today, AbbVie, a global biopharmaceutical company, announced preliminary data from the ongoing Phase 1/2b PCYC-1119 trial suggesting that the combination of ibrutinib (IMBRUVICA) plus carfilzomib with or without dexamethasone was well tolerated in relapsed or refractory patients with multiple myeloma (MM), with an initial objective response rate (ORR) of 62%.
2005: Proteolix enters into a Collaboration Agreement with Ligand (formerly CyDex Pharmaceuticals) for a Captisol-enabled IV formulation of carfilzomib to solve stability and solubility issues, and enable a reduced drug load
This is the first study to look at carfilzomib as a front-line treatment of patients with myeloma, a type of cancer that arises in the plasma cells.
Onyx (ONXX) paid $276 million up front to acquire the privately held Proteolix to get to its multiple myeloma drug carfilzomib.
Onyx may pay up to $575 million more in milestone payments for development and regulatory approvals of the experimental drug, carfilzomib, the company said in a statement.
Lymphoma - Pre-Clinical - Chemotherapy and Biologic Agents: Poster II Abstract #: 2765 Title: The Irreversible Proteasome Inhibitor Carfilzomib Interacts Synergistically with the Selective HDAC6 Inhibitor ACY-1215 in ABC- and GC-DLBCL and Mantle Cell Lymphoma Sensitive or Resistant to Bortezomib Authors Affiliated with the Following Institutions: Virginia Commonwealth University and University of Rochester Description: These findings indicate that combining the selective HDAC6 inhibitor ACY-1215 with carfilzomib (CFZ) synergistically in preclinical models induces apoptosis in low- and high-risk diffuse large B-cell lymphoma (DLBCL) and in mantle cell lymphoma (MCL) cells through a JNK-dependent process in association with G2M arrest, down-regulation of HR23B, and induction of DNA damage.
About ENDEAVOR The randomized ENDEAVOR (RandomizE d, OpeN Label, Phase 3 Study of Carfilzomib PlusDE xamethA soneV s Bortezomib Plus DexamethasO ne in Patients WithR elapsed Multiple Myeloma) trial of 929 patients evaluated Kyprolis in combination with low-dose dexamethasone, versus bortezomib with low-dose dexamethasone in patients whose multiple myeloma has relapsed after at least one, but not more than three prior therapeutic regimens.
This past summer carfilzomib (Kyprolis), a second generation proteasome inhibitor, was approved by the Food and Drug Administration (FDA) in the United States.
ASH Abstract #729: Impact of Prior Treatment on Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone in a Subgroup Analysis of the Phase 3 ENDEAVOR Study (NCT01568866) This preplanned, exploratory sub-analysis assessed treatment with Kyprolis and dexamethasone or bortezomib and dexamethasone in 929 total patients.
In addition, two poster presentations present data on trials evaluating investigational agents elotuzumab and carfilzomib in patients relapsed/refractory or intolerant to standard therapies.